Alnylam Pharmaceuticals Inc

Quantli Newsdesk

· 15 days ago

AstraZeneca's partner Ionis Pharmaceuticals saw shares plunge 24% after their jointly developed heart drug Wainua failed a critical Phase 3 trial. The setback eliminates a potential expansion into the large ATTR-CM heart disease market, though the drug remains approved for other uses.

Quantli Newsdesk

· a month ago

AstraZeneca shares fell as much as 10.6% in London after its experimental heart disease drug Wainua failed a late-stage trial, missing expectations for a company known for consistent clinical success. The market reaction was roughly twice what analysts expected based on the drug's financial impact alone, suggesting investors are reassessing the premium they've placed on AstraZeneca's pipeline credibility.

Quantli Newsdesk

· a month ago

Wainua, a gene-silencing drug co-developed by Ionis and AstraZeneca, missed its primary endpoint in a Phase 3 trial for ATTR-CM, a progressive heart disease affecting up to 500,000 people worldwide. The drug failed to show statistically significant cardiovascular benefit when added to standard care, though a subgroup not taking stabilizers showed nominal improvement. Ionis shares fell as much as 15% in premarket trading.